Carotenoids: A Family of 700+ Natural Pigments — Evidence-Based Overview of the 8 Core Compounds for Health

Educational reference page · This page summarizes what is currently known about carotenoids as a chemical family. It is not medical advice and does not promote any specific product. Statements with clinical implications are linked to peer-reviewed studies (PMID) and major regulatory positions (FDA, EFSA, NMPA, ANVISA). For each compound discussed below, a dedicated deep-dive page is linked at the bottom of the relevant section.

§1 What Is a Carotenoid? — The 8-Chemical Family Map

Carotenoids are a family of more than 700 fat-soluble natural pigments produced by plants, algae, certain bacteria, and a few fungi. Humans and most animals cannot synthesize carotenoids; we obtain them entirely from the diet (foods such as carrots, tomatoes, marigold-extracted lutein, microalgae, and salmon, where the pigment is concentrated up the food chain).

Although hundreds of carotenoids exist in nature, everyday nutrition and clinical evidence concentrate on roughly 8 core compounds, plus 2 minor compounds with niche relevance:

#	Compound	Class	Formula	Main Food / Microbial Source	Provitamin A activity
1	α-Carotene	Carotene (hydrocarbon)	C40H56	Carrot, pumpkin, sweet potato, maize	Yes (~50% of β-carotene)
2	β-Carotene	Carotene (hydrocarbon)	C40H56	Carrot, spinach, kale, sweet potato, Dunaliella salina (halophilic alga)	Yes (primary plant source · 12 µg β-carotene = 1 µg retinol activity equivalent, RAE)
3	β-Cryptoxanthin	Xanthophyll (hydroxylated)	C40H56O	Orange, papaya, red bell pepper, persimmon, maize	Yes (~50% of β-carotene)
4	Lutein	Xanthophyll (dihydroxy, ε-ring)	C40H56O₂	Marigold (Tagetes erecta), kale, spinach, egg yolk, broccoli, maize	No (ε-ring prevents BCO1 cleavage)
5	Zeaxanthin (and meso-Zeaxanthin)	Xanthophyll (dihydroxy, β-ring)	C40H56O₂	Maize, egg yolk, goji berry, marigold (minor) · meso-Z is generated in the retina from lutein	No
6	Lycopene	Carotene (hydrocarbon, acyclic)	C40H56	Cooked tomato, tomato paste, watermelon, pink grapefruit, guava	No (no β-ionone ring)
7	Astaxanthin	Xanthophyll (dihydroxy + diketo)	C40H52O4	Haematococcus pluvialis (freshwater microalga), Phaffia / Xanthophyllomyces yeast, salmon, shrimp, krill	No
8	Fucoxanthin	Xanthophyll (allenic, epoxide, acetate)	C42H58O6	Brown seaweeds (kelp, wakame, hijiki), diatoms (Phaeodactylum tricornutum)	No
(Minor)	Canthaxanthin	Xanthophyll (diketo)	C40H52O2	Rare in food · used as food coloring / aquaculture pigmenter · high-dose oral supplementation has historically caused reversible retinal crystals	No
(Minor)	Crocetin / Crocin	Apocarotenoid (C20 short-chain)	C20H24O4 / glycosides	Saffron stigma, gardenia fruit	No

Key family takeaway: When research or product labels say "carotenoid," they usually mean one of the 8 compounds above. Each has distinct chemistry, distinct dietary sources, distinct absorption and tissue distribution, and distinct clinical evidence. Generic statements like "carotenoids are antioxidants" are correct at the family level but understate how different the individual compounds are in practice.

§2 Two Sub-classes: Carotenes vs Xanthophylls — The Most Useful Dividing Line

All carotenoids share a 40-carbon polyene backbone built from 8 isoprene units. The most useful way to organize the family is by whether the molecule contains oxygen:

Dimension	Carotenes (pure hydrocarbon)	Xanthophylls (oxygenated)
Chemistry	C and H only · formula C40H56 family	Contain O groups (OH, C=O, epoxide, ester) · C40HxOy
Representatives	α-carotene · β-carotene · γ-carotene · lycopene	Lutein · zeaxanthin · β-cryptoxanthin · astaxanthin · fucoxanthin · canthaxanthin
Position in cell membranes	Buried deep in the hydrophobic membrane core (bilayer center)	Terminal OH / keto groups hydrogen-bond with phospholipid head groups · many xanthophylls (especially lutein and astaxanthin) span across the entire lipid bilayer
Provitamin A potential	Yes for α-carotene, β-carotene · No for lycopene (no β-ring)	Yes for β-cryptoxanthin only · No for lutein, zeaxanthin, astaxanthin, fucoxanthin (ε-ring, keto groups, or allenic structure prevent BCO1 cleavage)
Antioxidant emphasis	Strong physical quenching of singlet oxygen (lycopene is the most efficient single-compound quencher in the family, k_q ≈ 31 × 10⁹ M⁻¹ s⁻¹) · breaks lipid peroxidation chains in the membrane core	Transmembrane antioxidant action (astaxanthin's bipolar orientation is classic) · blue-light filtering (lutein, zeaxanthin: macular pigment) · UCP1 modulation (fucoxanthin, unique)
Best-studied hard-endpoint RCTs	CARET, ATBC (β-carotene in smokers — negative); FDA Qualified Health Claims 2005 (lycopene, prostate — "very limited credible evidence")	AREDS, AREDS2 (lutein + zeaxanthin in age-related macular degeneration); Astaxanthin meta-analyses for skin, oxidative stress, ART outcomes

Why this split matters for users

A common search question is: "Carotenoids — which ones should I actually pay attention to?" The most honest answer is to think in two sub-classes:

Carotenes — useful mainly as food-based sources of vitamin A (developing-world nutrition programs, fortified foods) and for whole-body lipid-phase antioxidant capacity (tomato/lycopene for cardiovascular biomarkers, β-carotene for skin photoprotection). The negative trials in smokers (CARET, ATBC, discussed in §6) apply specifically to high-dose isolated β-carotene supplementation and not to whole-food intake.
Xanthophylls — useful mainly as tissue-targeted compounds: lutein and zeaxanthin for macular pigment density and visual function; astaxanthin for multi-organ membrane antioxidant action with the largest randomized-trial base in skin, oxidative stress, and reproductive outcomes; fucoxanthin uniquely for adipose UCP1-mediated metabolic effects.

Throughout the rest of this page, results are presented compound-by-compound, with cross-links to the deep-dive sub-pages.

§3 Where Carotenoids Come From — Biosynthesis and Food

Carotenoids are made in plants, algae, and microbes

The plant/microbial pathway condenses isoprene units into a C40 backbone (phytoene), which is then desaturated to lycopene. Lycopene is the central branch point: cyclization at one or both ends produces α-carotene and β-carotene; further hydroxylation yields β-cryptoxanthin → zeaxanthin and lutein; β-ketolation (in microalgae such as Haematococcus pluvialis and bacteria such as Paracoccus) yields canthaxanthin and astaxanthin; allenic-epoxide modification (in brown algae and diatoms) yields fucoxanthin.

This is why bioengineered yeast and E. coli strains used to produce carotenoids are typically designed to make lycopene first, then re-cyclize or further functionalize.

Main dietary sources at a glance

Approximate concentrations per 100 g edible portion (these vary widely by variety, ripening stage, and cooking):

Compound	Top food sources (approx mg/100 g)
β-Carotene	Carrot (~8) · sweet potato (~8) · kale (~9) · spinach (~6) · Dunaliella dried powder (>40,000)
α-Carotene	Carrot (~3.5) · pumpkin (~4) · red pepper (~0.6)
β-Cryptoxanthin	Red pepper (~2.2) · persimmon (~1.4) · papaya (~0.8) · orange (~0.1)
Lycopene	Cooked tomato paste (~15–30) · watermelon (~4.5) · pink grapefruit (~1.5) · raw tomato (~3.0)
Lutein + Zeaxanthin	Kale (~22 + 0.2) · spinach (~12 + 0.3) · maize (~0.6 + 0.5) · egg yolk (~0.4 + 0.2)
Astaxanthin	Haematococcus pluvialis biomass (>10,000) · Arctic shrimp (~1.2) · salmon flesh (~1.1) · krill oil (~0.1–1.0)
Fucoxanthin	Kelp / wakame (~0.1–2.8) · hijiki (~1.5–3.3) · diatoms (microalgal raw material, not food)

Processing and matrix effects matter a lot

Three rules apply across the whole family:

Heat + fat dramatically improve absorption. Cooking tomato in olive oil triples to quintuples lycopene absorption compared with raw tomato, partly through trans → cis isomerization and partly through breakdown of the plant cell matrix (Stahl 2001 · PMID 11340098).
Dietary fat is universal. All carotenoids are fat-soluble; absorption from a meal without fat is much lower. Co-ingesting carotenoids with olive oil, full-fat yogurt, eggs, or avocado raises β-carotene absorption from ~6% to ~30%.
Genetic variation in BCO1/BCMO1 (the enzyme that converts β-carotene to retinal) affects how efficiently each person makes vitamin A from carotene precursors. A meaningful fraction of the population are "low converters"; for them, dietary or supplemental retinol meets vitamin A needs more reliably than β-carotene.

§4 How Carotenoids Work — Common Mechanisms and Compound-Specific Specialties

Five mechanisms shared across the family

Physical quenching of singlet oxygen (¹O₂). The conjugated polyene chain absorbs excitation energy from singlet oxygen and dissipates it as heat, without itself being consumed in a chemical reaction. Lycopene is the most efficient single-compound quencher in the family (k_q ≈ 31 × 10⁹ M⁻¹ s⁻¹); β-carotene, astaxanthin, lutein, and zeaxanthin follow at lower but still high rates. By comparison, α-tocopherol's quenching rate is roughly two orders of magnitude lower.
Lipid-peroxidation chain breaking. Carotenoids embed in phospholipid bilayers and lipoprotein cores (LDL, VLDL, HDL) and donate hydrogen atoms to lipid peroxyl radicals, terminating chain reactions. Where the molecule sits in the membrane — buried in the core (β-carotene) versus spanning the bilayer (lutein, astaxanthin) — strongly influences which lipid environments it protects most.
NRF2 / ARE activation. Oxidative metabolites of carotenoids modify reactive cysteines on Keap1, allowing NRF2 to translocate to the nucleus and upregulate Phase II detoxification enzymes (HO-1, NQO1, glutamate-cysteine ligase, SOD).
NF-κB suppression and anti-inflammatory signaling. Many carotenoids stabilize IκBα, blocking p65 nuclear translocation and downregulating IL-6, TNF-α, COX-2, and iNOS. Astaxanthin has the strongest randomized-trial evidence for reductions in inflammatory and oxidative markers (Ma 2022 meta · PMID 35091276).
Pigmentation and light biology. Carotenoids are the accessory pigments of photosynthesis (absorbing 400–500 nm blue light and transferring energy to chlorophyll). In humans they produce a benign skin pigmentation at very high intakes ("carotenoderma" — yellow-orange palms and soles, fully reversible), supply the only two pigments of the retinal macula (lutein, zeaxanthin), and color salmon flesh and flamingo plumage through dietary uptake.

Specialty mechanisms — one per compound

Compound / sub-class	Specialty mechanism	Clinical relevance
α-Carotene, β-carotene, β-cryptoxanthin	BCO1/BCMO1 central 15,15' cleavage → retinal → retinol. Activity is feedback-down-regulated when vitamin A status is adequate, which limits toxicity.	Primary plant source of vitamin A; the supplementation form of choice in pregnancy, because preformed retinyl palmitate at high dose is teratogenic and β-carotene self-limits.
Lycopene	11 conjugated double bonds, acyclic, top singlet-oxygen quencher; modulates IGF-1 and androgen-receptor signaling in vitro (mechanistic basis for prostate research).	Cardiovascular surrogate markers (BP, LDL oxidation), tomato-paste skin photoprotection, FDA Qualified Health Claims (prostate, ovarian, pancreatic, gastric cancer) judged as "very limited credible evidence".
Lutein + zeaxanthin (+ meso-zeaxanthin)	Selectively transported to the retina via StARD3 and GSTP1, where they concentrate >1,000-fold above plasma. They form the macular pigment, filter blue light (peak absorbance ~445 nm), and the central foveal meso-zeaxanthin is generated in situ from lutein.	Macular pigment optical density (MPOD), age-related macular degeneration progression (AREDS2), digital eye strain.
Astaxanthin	Bipolar transmembrane orientation (terminal hydroxy + keto groups on both ends span the bilayer); does not generate pro-oxidant intermediates at supra-physiological doses, unlike β-carotene; strong NRF2 activator and NF-κB suppressor.	Skin moisture and elasticity, systemic oxidative stress and inflammation markers, ART outcomes in PCOS, asthenopia, exercise.
Fucoxanthin	Metabolite fucoxanthinol upregulates uncoupling protein 1 (UCP1) in white adipose tissue → "browning" + increased basal metabolic rate. Also activates AMPK and modulates PPAR-γ.	The only carotenoid with a randomized human signal for thermogenic / metabolic effects — weight, body fat, NAFLD, HbA1c (largely in combination products).

Honest framing: Carotenoids share several mechanisms but each compound has a structurally driven speciality. Generic "antioxidant" claims understate this specialization; the clinically meaningful effects are sub-class specific.

§5 Compound-by-Compound — The 6 Core Carotenoids in Practice

This section gives a brief, evidence-anchored summary of the 6 most clinically studied carotenoids. Each has its own dedicated deep-dive sub-page; this hub page only sets context.

§5.1 β-Carotene — Plant Vitamin A and Skin Photoprotection (with an Important Smoker Caveat)

Core role. β-Carotene is the most efficient plant source of provitamin A. The BCO1/BCMO1 cleavage enzyme is feedback-regulated, so dietary β-carotene rarely causes vitamin A toxicity — the body simply converts less when vitamin A stores are full. This makes β-carotene the preferred form of vitamin A supplementation in pregnancy and in public-health programs targeting vitamin A deficiency (Cochrane review · Imdad 2017 · PMID 28282701).

Other supported uses. A meta-analysis of 7 randomized controlled trials (β-carotene 15–30 mg/day for ≥10 weeks) found a dose-related increase in minimal erythema dose (MED), i.e. modest protection against UV-induced sunburn (Köpcke 2008 · Photochem Photobiol · PMID 18086246). A long-term arm of the Physicians' Health Study II (β-carotene 50 mg every other day for ~18 years) found higher scores on cognitive testing in supplemented men, although shorter-term arms showed no effect (Grodstein 2007 · Arch Intern Med · PMID 17998490).

⚠️ Smoker cross-link caveat (cluster-wide red line): Two large randomized trials in heavy smokers and asbestos-exposed workers found that high-dose β-carotene supplementation increased lung cancer:

CARET (Omenn 1996 · NEJM · PMID 8602180) randomized 18,314 heavy smokers, former smokers, and asbestos-exposed workers to β-carotene 30 mg/day plus retinyl palmitate 25,000 IU/day versus placebo. The trial was stopped early when interim analysis showed lung cancer incidence +28%, all-cause mortality +17%, and cardiovascular mortality +26% in the supplemented group.
ATBC (1994 · NEJM · PMID 8127329) randomized 29,133 Finnish male smokers (ages 50–69) to α-tocopherol 50 mg/day, β-carotene 20 mg/day, both, or placebo. In the β-carotene arm, lung cancer incidence was +18% (NEJM original text: "change in incidence, 18 percent"), and cardiovascular mortality was elevated.

These findings apply specifically to high-dose isolated β-carotene supplementation in current or former smokers and asbestos-exposed individuals, not to whole-food intake. Most major health agencies recommend that people in these groups avoid β-carotene supplements at doses of 20 mg/day or higher. See the dedicated callout box in §6.

Deep-dive sub-page: /ingredients/beta-carotene/

§5.2 Lutein and §5.3 Zeaxanthin — The Macular Pigment

Core role. Lutein and zeaxanthin are the only two carotenoids that selectively accumulate in the retinal macula, where, together with meso-zeaxanthin (generated in situ from lutein), they form the macular pigment. The macular pigment filters short-wavelength blue light and quenches reactive oxygen species generated by intense retinal illumination. Humans cannot synthesize either compound; both must come from the diet (dark leafy greens, maize, egg yolk, marigold-extracted supplements).

AREDS and AREDS2 — the landmark trials.

AREDS (2001 · Arch Ophthalmol · PMID 11594942) randomized 3,640 adults aged 55–80 with intermediate or advanced age-related macular degeneration (AMD) in one eye to a daily supplement of vitamin C 500 mg + vitamin E 400 IU + β-carotene 15 mg + zinc 80 mg + copper 2 mg, or placebo. Over 5 years, the supplement reduced progression to advanced AMD by ~25%.
AREDS2 (Chew 2013 · JAMA · PMID 23644932) randomized 4,203 adults aged 50–85 in a 2×2 factorial design to lutein 10 mg + zeaxanthin 2 mg (with β-carotene removed and zinc reduced from 80 → 25 mg) versus placebo, and DHA 350 mg + EPA 650 mg versus placebo. The primary endpoint comparing L+Z to no L+Z was not statistically significant in the overall population (~10% reduction in progression). However, in a pre-specified secondary analysis (Report 3 · Chew 2014 · PMID 24310343), participants in the lowest baseline dietary L+Z quartile had a 26% reduction in progression to advanced AMD with L+Z supplementation. AREDS2 also showed that L+Z safely replaces β-carotene without the smoker risk — leading to the current AREDS2 formulation. A 10-year follow-up (Chew 2022 · JAMA Ophthalmol · PMID 35653117) confirmed durable benefit.

Other supported uses. Lutein 10 mg + zeaxanthin 2 mg per day for 6 months improved measures of visual fatigue, headache, and eye discomfort in adults with high screen exposure (Stringham 2017 · Foods · PMID 28661438). The CARES trial (Hammond 2017 · Front Aging Neurosci · PMID 28824416) found improvements in cognitive measures (learning, verbal fluency, memory) in community-dwelling older adults supplemented with L 10 + Z 2 mg/day for 12 months. The Akuffo MOST AMD trial (2015 · Eye (London) · PMID 25976647) studied a three-compound formulation (L + Z + meso-Z) in n=67 early AMD patients over 36 months and showed that adding meso-zeaxanthin to L+Z further increases macular pigment density specifically at the foveal centre. A separate Akuffo-group programme, CREST (methodology Akuffo 2014 Ophthalmic Epidemiol · PMID 24621122 · Report 1 healthy-eye cohort Nolan 2016 IOVS · PMID 27367585), reports contrast-sensitivity and visual-performance outcomes for the same L + Z + meso-Z formulation in healthy and early-AMD arms.

Dose convention. The complete AREDS2 evidence applies to L 10 mg + Z 2 mg/day in combination. Reduced or split doses cannot inherit the AREDS2 endpoint claims directly.

Regional regulatory difference. US, China, and Brazil permit broad eye-health labeling for L/Z. EFSA (2012 ANS Panel) declined to authorize Art.13.1 health claims for lutein or zeaxanthin in macular health, citing insufficient evidence to establish a cause-and-effect relationship. Statements about macular benefit should therefore be regionally appropriate.

Deep-dive sub-pages: /ingredients/lutein/ and /ingredients/zeaxanthin/

§5.4 Astaxanthin — The Transmembrane Xanthophyll

Core role. Astaxanthin is a xanthophyll with a unique bipolar transmembrane orientation: the two terminal rings, each bearing both a hydroxyl and a keto group, anchor in the polar surfaces of the lipid bilayer, while the conjugated polyene chain spans the hydrophobic core. This geometry lets astaxanthin protect both the inner and outer leaflets of cell membranes simultaneously — a property that distinguishes it from carotenes such as β-carotene (buried in the core) and even from other xanthophylls.

Best-supported evidence (meta-analyses).

Oxidative stress and inflammation. A meta-analysis of 12 RCTs (n=380, doses 2–24 mg/day, durations 2–12 weeks) found significant reductions in malondialdehyde, IL-6, and TNF-α (Ma 2022 · Antioxidants · PMID 35091276).
Skin moisture and elasticity. A meta-analysis of 11 RCTs (n=481) reported SMD 0.49 for skin moisture and 0.46 for elasticity (both statistically significant), with no significant effect on wrinkle depth in this aggregate (Donoso 2021 · Pharmacol Res / Nutrients · PMID 34578794). This is the only family-wide finding where carotenoid effects on hydration and elasticity have crossed the meta-analysis bar in humans.
Assisted-reproduction outcomes. Recent RCTs and a 2024 meta-analysis report improvements in IVF/ICSI clinical-pregnancy rates with astaxanthin co-supplementation in women undergoing ART, with mechanisms tied to follicular oxidative stress reduction (Fereidouni 2024 · PMID 38916710; Rodrigues 2025 meta · PMID 39269488).

Other supported areas (Tier B / B+ single RCTs).

Visual fatigue / asthenopia in adults with high screen exposure (Hecht 2025 · PMID 40014233; Tian 2021 · PMID 35096941).
Exercise performance and recovery (Liu 2024 meta of 11 RCTs · PMID 38243785).
Cardiovascular biomarkers and lipid profile (Xia 2020 · PMID 32755613; Ciaraldi 2023 prediabetes RCT · PMID 36999233).
Glycemic and insulin-sensitivity outcomes (Urakaze 2021 · PMID 34959932; Mashhadi 2018 · PMID 29384321).

Source and regulatory context. Most commercial astaxanthin for human supplementation is sourced from the microalga Haematococcus pluvialis. Synthetic astaxanthin (a 1:2:1 stereoisomer mix) is not permitted for human food use in China (NMPA 2010 Notice 17). Multiple GRAS notifications (GRN 294, 580, 700) cover use in the United States. EFSA (2014, updated 2020) set an Acceptable Daily Intake of 0.2 mg/kg body weight/day, equivalent to roughly 8 mg/day for an adult.

Deep-dive sub-page: /ingredients/astaxanthin/ (full Layer A page already published)

§5.5 Lycopene — Cardiovascular Surrogates and the Tomato-Paste Story

Core role. Lycopene is the most efficient single-compound singlet-oxygen quencher in the carotenoid family. It is acyclic (no β-ring), so it is not a vitamin A precursor. Its red colour and stability make it widely used as a food colorant (E160d in the EU); its clinical relevance focuses on cardiovascular surrogate markers and on prostate health, with important regulatory nuance.

Cardiovascular surrogates. A 2017 systematic review and meta-analysis of randomized intervention trials found that lycopene supplementation (typically 10–30 mg/day for 8–12 weeks) reduced systolic blood pressure by ~5 mmHg and LDL cholesterol, and reduced LDL oxidation markers (Cheng 2017 · Crit Rev Food Sci Nutr · PMID 28129549; Ried 2011 · Maturitas · PMID 21163596). Hard cardiovascular endpoints (MACE) have not been tested in a dedicated large RCT.

Skin photoprotection. Tomato paste (containing ~16 mg lycopene/day) consumed with olive oil for 10 weeks increased the minimal erythema dose by ~40% (Stahl 2001 · J Nutr · PMID 11340098). Smaller dermatology RCTs report similar effects (Rizwan 2011 · Br J Dermatol · PMID 20854436; Grether-Beck 2017 · PMID 27662341).

Prostate health — important regulatory caveat. In 2005, the US FDA reviewed a citizen petition for health claims linking lycopene and tomato products to prostate, ovarian, pancreatic, and gastric cancer. The FDA permitted Qualified Health Claims with the following required wording (or equivalent): "Very limited credible evidence suggests that consuming lycopene may reduce the risk of [prostate / ovarian / pancreatic / gastric] cancer; however, the FDA concludes that this evidence is very limited." Subsequent meta-analyses (Chen 2015 · Medicine · PMID 26287411; Wang 2015 · PMID 26372549) report weak associations in observational data. No claim of disease prevention or treatment should be made.

Regional regulatory nuance. EFSA (2010–2011) declined all Art.13.1 health claims for lycopene (cardiovascular, antioxidant, prostate, skin). In the EU, lycopene is permitted as a food colorant (E160d) and as a Novel Food (synthetic, tomato-derived, Blakeslea trispora fermentation-derived), but no functional health claim may be made on EU labels. China (NMPA 2008 Novel Food approval) and Brazil (ANVISA RDC 243/2018) permit general antioxidant labeling. This regional matrix matters when reading lycopene products marketed internationally.

Carotenodermia note. Sustained intake of ≥75 mg/day lycopene (typically from very tomato-rich diets) can cause "lycopenemia" — reversible yellow-orange skin pigmentation, harmless and disappearing with dose reduction.

Deep-dive sub-page: /ingredients/lycopene/

§5.6 Fucoxanthin — The Only Carotenoid with a Thermogenic Signal

Core role. Fucoxanthin is an allenic xanthophyll found in brown seaweeds (kelp, wakame, hijiki) and in diatoms (Phaeodactylum tricornutum). After oral intake it is metabolized to fucoxanthinol, which upregulates uncoupling protein 1 (UCP1) in white adipose tissue, supporting the "browning" of white fat and a modest increase in basal metabolic rate. It also activates AMPK and modulates PPAR-γ. This is the only mechanism in the carotenoid family that translates into a measurable thermogenic / metabolic signal in randomized human trials.

Best-supported evidence (note: most trials use combination formulations, which limits attribution to fucoxanthin alone).

Weight and body fat — Xanthigen formulation [combination]. A 16-week RCT in 151 obese pre-menopausal women with non-alcoholic fatty liver disease used Xanthigen™ (a brown-seaweed + pomegranate-seed-oil formulation supplying 2.4 mg fucoxanthin/day). The supplemented group lost an average of 5.5 kg total weight and ~3.5 kg body fat versus placebo, with measured increases in resting metabolic rate and decreases in liver fat (Abidov 2010 · Diabetes Obes Metab · PMID 19840063). Because Xanthigen contains other active ingredients, results cannot be attributed to fucoxanthin alone.
Metabolic syndrome — single-agent 12 mg/day × 12 weeks. A small (n=28) RCT of 12 mg/day fucoxanthin in metabolic-syndrome adults showed improvements in composite metabolic-syndrome markers (López-Ramos 2023 · J Med Food · PMID 37405785).
HbA1c and UCP1 genotype. An 8-week trial of 2 mg/day fucoxanthin-enriched akamoku oil in 60 adults found greater HbA1c reductions in carriers of the UCP1 G/G allele, supporting the proposed UCP1-mediated mechanism (Mikami 2017 · J Nutr Sci · PMID 28620480).
NAFLD — LMF-HSFx formulation [combination]. A 24-week RCT of low-molecular-weight fucoidan combined with high-stability fucoxanthin reported improvements in liver enzymes and steatosis markers (Shih 2021 · Mar Drugs · PMID 33809062). Again attribution to fucoxanthin alone is limited.
Cognitive — Phaeodactylum 1100 mg/day (containing 8.8 mg fucoxanthin) × 12 weeks showed positive cognitive signals with no serious adverse events (Yoo 2024 · Nutrients · PMID 39275314).

Regulatory status. Fucoxanthin is not yet broadly authorized as a single-compound food supplement: in the EU it is subject to Novel Food evaluation for individual sources; in the US several manufacturers have self-affirmed GRAS or filed NDIs; in China and Brazil status is per-application. Acute safety appears favourable up to 60 mg/day for 4 weeks in healthy adults (Hashimoto 2017 · Food Funct).

Deep-dive sub-page: /ingredients/fucoxanthin/ (full Layer A page already published)

§6 Cluster Clinical Evidence — Including Cautionary Findings

⚠️ Cautionary Findings — Please Read Before Taking Any Single High-Dose Carotenoid Supplement

High-dose isolated β-carotene supplementation has been shown to increase lung cancer in smokers in two large randomized trials. Anyone who currently smokes, recently smoked, or has a history of asbestos exposure should not take β-carotene supplements at doses of 20 mg per day or higher. Whole-food intake of β-carotene from carrots, leafy greens, sweet potatoes, and other vegetables is not implicated by these trials and remains compatible with standard dietary guidance.

The trials in question are:

CARET (Omenn 1996 · NEJM · PMID 8602180) — 18,314 heavy smokers, former smokers, and asbestos-exposed workers · β-carotene 30 mg/day + retinyl palmitate 25,000 IU/day vs placebo · trial stopped early · lung cancer +28%, all-cause mortality +17%, CV mortality +26%.
ATBC (1994 · NEJM · PMID 8127329) — 29,133 Finnish male smokers age 50–69 · β-carotene 20 mg/day · lung cancer +18% (NEJM original wording: "change in incidence, 18 percent") · 18-year postintervention follow-up shows the supplement-related lung-cancer signal attenuated but did not fully reverse (Virtamo 2014 · PMID 24338499).

A related cautionary trial from the vitamin E family — SELECT (Klein 2011 · JAMA · PMID 21990298) — randomized 35,533 healthy men aged ≥50 to vitamin E 400 IU/day, selenium 200 µg/day, both, or placebo, and found a 17% relative increase in prostate cancer with vitamin E supplementation. SELECT did not test a carotenoid, but it carries the same broader lesson: isolated high-dose antioxidant supplementation in already-nourished populations does not reliably reproduce the broad benefits seen with dietary patterns rich in colourful whole foods, and may even cause harm in specific subgroups.

Supported (mostly positive) findings, by trial

Trial / claim	Compound · type	Result	Source
AREDS original formulation	β-carotene 15 mg + vit C 500 mg + vit E 400 IU + Zn 80 mg + Cu 2 mg · DB-PC RCT n=3,640 · 5 yr	Progression to advanced AMD −25%	PMID 11594942
AREDS2 L+Z replaces β-carotene	Lutein 10 mg + zeaxanthin 2 mg · DB-PC RCT n=4,203 · 5 yr · 2×2 factorial	Primary endpoint (L+Z vs no L+Z, full population) NS (~−10%); secondary in lowest baseline L+Z dietary quartile −26% (Report 3 · PMID 24310343); L+Z safely replaces β-carotene in smokers	PMID 23644932
AREDS2 10-yr follow-up	as above · n=3,882 long-term FU	Durable AMD benefit at 10 yr; L+Z replacement remains safe	PMID 35653117
Köpcke sunburn meta-analysis	β-carotene 15–30 mg/d × ≥10 wk · meta of 7 RCTs	Minimal erythema dose ↑ in dose-related fashion	PMID 18086246
Lycopene CV risk markers meta	10–30 mg/d × 8–12 wk · multiple RCTs pooled	SBP ↓ ~5 mmHg · LDL-C ↓ · LDL oxidation markers ↓	PMID 28129549
Astaxanthin oxidative/inflammatory meta	2–24 mg/d × 2–12 wk · 12 RCTs n=380	MDA ↓ · IL-6 ↓ · TNF-α ↓ (all p<0.05)	PMID 35091276
Astaxanthin skin meta	mostly 6 mg/d × ≥8 wk · 11 RCTs n=481	Skin moisture SMD 0.49 · elasticity SMD 0.46 (both p<0.05) · wrinkle depth NS	PMID 34578794
Fucoxanthin weight (Xanthigen [combination])	2.4 mg FX/d × 16 wk · DB-PC RCT n=151	Weight −5.5 kg · body fat −3.5 kg vs placebo · RMR ↑	PMID 19840063
Lutein + zeaxanthin digital eye strain	L 10 + Z 2 mg/d × 6 mo · DB-PC RCT n=59	Visual fatigue / headache / discomfort scores ↓ · MPOD ↑	PMID 28661438
Vitamin A supplementation in children (β-carotene path)	Cochrane review · multiple RCTs in developing-country children	All-cause mortality and morbidity ↓ in vitamin-A-deficient populations	PMID 28282701

How to read this evidence as a whole

Across the carotenoid family, the strongest randomized-trial evidence is for age-related macular degeneration progression (AREDS / AREDS2, lutein + zeaxanthin) and for skin moisture and elasticity (astaxanthin meta-analysis). Both are meta-analysis-supported.
A second tier of evidence exists for cardiovascular surrogate markers (lycopene), skin photoprotection (β-carotene and lycopene), oxidative and inflammatory markers (astaxanthin), and metabolic / weight outcomes (fucoxanthin in combination products). These are RCT-supported but typically on intermediate markers rather than hard clinical endpoints.
A single high-dose isolated supplement of one carotenoid is not a substitute for the whole-food carotenoid intake supplied by a diverse colourful diet, and in the specific case of β-carotene supplements in smokers, it has caused measurable harm.

§7 Safety, Upper Limits, and Cautions

Family-wide pattern

Aspect	Notes
Common adverse effects	Carotenoid intake is generally very well tolerated. The most visible effect of sustained high intake is carotenodermia — yellow-orange pigmentation of the palms, soles, and nasolabial folds. It is fully reversible and not harmful. Occasional mild gastrointestinal discomfort with concentrated supplements.
Absorption	All carotenoids are fat-soluble. Taking with a fat-containing meal can double or triple absorption compared with empty-stomach intake.
Drug interactions	Orlistat and bile-acid sequestrants reduce absorption of all fat-soluble vitamins and carotenoids. High-dose isolated β-carotene can competitively reduce lutein and zeaxanthin absorption (they share SR-BI intestinal transporters) — one reason the AREDS2 formulation removed β-carotene.
Pregnancy	Food-level intake and modest β-carotene supplementation (≤6 mg/day) are considered safe; β-carotene is preferred over preformed retinyl palmitate, which is teratogenic at high doses. Long-term high-dose carotenoid supplementation in pregnancy has not been adequately studied.
Children	Food-level intake is safe; WHO/UNICEF programs use β-carotene and retinyl palmitate in regions with vitamin A deficiency. Routine high-dose carotenoid supplements are generally not recommended outside such programs.
Storage	Carotenoids are easily oxidized by light; soft-gel capsules, microencapsulation, nitrogen-flush packaging, and refrigerated transport are standard for quality formulations.

Compound-specific cautions

Compound	Caution
β-Carotene	Smokers / former smokers / asbestos-exposed individuals: avoid supplemental β-carotene at doses ≥20 mg/day. Long-term high-dose can also cause carotenodermia.
Lycopene	Sustained intake ≥75 mg/day can cause reversible lycopenemia (skin pigmentation).
Lutein / zeaxanthin	Excellent safety record across AREDS2's 5- and 10-year follow-ups; no smoker-specific risk. The cluster's safest sub-class.
Astaxanthin	Excellent tolerance; occasional faint orange tint to faeces or skin. Source matters for crustacean-allergy populations — algal-source astaxanthin contains no shellfish allergen. Excluded from infant formulations under both EFSA and NMPA frameworks.
Fucoxanthin	Doses ≥10 mg/day occasionally cause mild GI symptoms that adapt. 60 mg/day for 4 weeks reported no serious adverse events in healthy adults.
Canthaxanthin	Not recommended as a human supplement. Sustained high-dose oral use has historically caused reversible retinal crystal deposition and is flagged by EFSA and FDA.

Upper-intake reference values

Compound	US (IOM / NDI)	EU (EFSA)	China (NMPA)	Brazil (ANVISA)
β-Carotene	No UL (BCO1 self-limits); smokers ≤20 mg/day	No UL; smokers ≤7 mg/day supplemental	GB 14880 nutrient fortifier; registered supplements per dose	IN 28/2018
Lutein	No UL; ADI 1 mg/kg bw/day (EFSA 2006) ≈ 70 mg/day for an adult	ADI 1 mg/kg bw/day	GB 14880; registered supplements	RDC 243/2018 (carotenoid positive list)
Zeaxanthin	No UL; ADI 0.75 mg/kg bw/day ≈ 53 mg/day adult	ADI 0.75 mg/kg bw/day	2017 Novel Food ≤4 mg/day (marigold source)	IN 28/2018
Lycopene	No UL	ADI 0.5 mg/kg bw/day ≈ 30 mg/day adult	2008 Novel Food	RDC 243/2018
Astaxanthin	NDI up to 24 mg/day short-term	EFSA 2020 supplement limit 8 mg/day adult; ADI 0.2 mg/kg bw/day	NMPA 2010 Notice 17: Haematococcus powder ≤0.8 g/day; algal oil ≤240 mg/day	RDC 243/2018 ≤12 mg/day
Fucoxanthin	NDI not independently characterized	Novel Food pending for several source materials	Per-application	Not listed in IN 28/2018

§8 Global Regulatory Snapshot

This section summarizes the labeling and approval framework in the four major regions where carotenoid products are commonly marketed.

Compound	China NMPA	US FDA	Brazil ANVISA	EU EFSA
β-Carotene	GB 2760 food additive (colour) + GB 14880 nutrient fortifier + registered supplements + Dunaliella Novel Food	21 CFR colour additive + DSHEA dietary supplement + recognized vitamin A precursor	IN 28/2018 (restricted); smoker high-dose cautionary statements required	E 160a (ii) food additive + vitamin A identity claim authorized; smoker high-dose red line
Lutein	GB 14880 fortifier + lutein ester registered as "supports visual fatigue relief" (marigold-source on positive list; fermentation/microalgal sources require Novel Food filing)	Multiple GRAS notifications (e.g. GRN 140, 221) + DSHEA supplement; AMD-area Qualified Health Claim still under review	RDC 243/2018 positive list + general visual-health labeling	Legally sold as supplement; EFSA 2012 declined Art.13.1 "macular health / visual maintenance" health claims (insufficient evidence); only general antioxidant-style Art.13.1 claims available
Zeaxanthin	2017 Novel Food (marigold ≤4 mg/day); 2024 meso-zeaxanthin Novel Food; combined with lutein in registered supplements	Multiple GRAS notifications including marigold-derived zeaxanthin + self-affirmed GRAS for meso-zeaxanthin + DSHEA supplement	RDC 243/2018 positive list + visual-health labeling	ANS Panel safety opinion 2012 + EU Novel Food Union List 2017/2470; Reg 432/2012 does not authorize a stand-alone health claim
Lycopene	2008 Novel Food + registered supplements for general antioxidant / immune-support framing	Multiple GRAS notifications + DSHEA + 4 Qualified Health Claims (2005) for prostate, ovarian, pancreatic, gastric cancer — all classified as "very limited credible evidence" with mandatory disclaimer wording	RDC 243/2018 + general antioxidant labeling	EFSA 2010–2011 declined all Art.13.1 lycopene functional claims (cardiovascular, antioxidant, prostate, skin); permitted only as E160d food colour and Novel Food; no functional health claim may appear on EU labels
Astaxanthin	2010 Notice 17 Haematococcus Novel Food + 31 registered supplements (including 19 "immune-support" SKUs); synthetic astaxanthin prohibited in human food	Multiple GRAS notifications (GRN 294, 580, 700) + DSHEA + Structure/Function claims	RDC 243/2018 ≤12 mg/day + IN 418 "supports skin health" (≥3 mg/day) — one of the few markets permitting a specific functional claim	EFSA declined health claims 2009–2011; 2014/2020 ADI 0.2 mg/kg bw/day; supplement cap effectively ≤8 mg/day adult
Fucoxanthin	Novel Food filings ongoing; not broadly marketed	Self-affirmed GRAS + DSHEA + selected NDI notifications	Not listed in IN 28/2018; per-application review	Novel Food evaluation pending for several source materials

Key takeaways for international readers

The EU is the strictest market for carotenoid functional claims. EFSA has refused most Art.13.1 applications across the family. EU-market labels for lycopene, lutein, zeaxanthin, and astaxanthin generally cannot make functional health claims; only identity and general antioxidant statements apply.
China, the US, and Brazil are more permissive for product registration, but each maintains specific dose ceilings and source restrictions. China's restriction of synthetic astaxanthin to non-food uses is the most distinctive regulatory line in the family.
The smoker / β-carotene cautionary statement is recognized across every major market. It is a public-health red line, not a regional preference.
The trend in supplement regulation is towards conservative dose limits and evidence-based claims. The 2024 EFSA reassessment of vitamin E (UL lowered from 1000 mg/day to 300 mg/day) is a recent example of this direction; while no equivalent carotenoid revision has occurred, the cluster-wide direction is towards stricter labeling.

§8.5 Mandatory regulatory disclaimers (educational hub copy)

§9 How to Choose Carotenoid Products and Foods — A Practical Decision Framework

Five practical dimensions

Natural vs synthetic. β-Carotene is available from both natural (microalgal Dunaliella, with a characteristic ~40% 9-cis / ~50% all-trans isomer mix) and synthetic (all-trans dominant) sources; both are equivalent on safety, and the smoker risk applies to total dose regardless of source. Astaxanthin is the one carotenoid where source matters legally: synthetic astaxanthin is not permitted for human food in China, leaving algal-sourced (Haematococcus pluvialis) and yeast-sourced (Phaffia / Xanthophyllomyces) as the principal options for that market. Lutein and zeaxanthin clinical evidence is built largely on marigold-extracted free-form material; fermentation-derived material requires independent validation.
Single compound vs mixed-carotenoid complex. A mixed carotenoid complex (e.g. β-carotene + α-carotene + lutein + zeaxanthin + lycopene + β-cryptoxanthin) mimics the natural dietary pattern and avoids competitive inhibition at the shared SR-BI intestinal transporter that occurs with single high-dose β-carotene. The current expert consensus is food first, with targeted single-compound supplementation only for specific tissue / outcome reasons (e.g. lutein + zeaxanthin for AMD risk, astaxanthin for skin or oxidative stress, fucoxanthin for metabolic-syndrome adjunct).
Formulation: oil-based softgel, microencapsulated, or crystalline. Oil-based softgels (olive oil, MCT, sunflower oil carrier) generally have the best bioavailability across the family. Microencapsulated forms (gum-arabic, modified starch) suit tablets and functional foods. Crystalline material requires dietary fat to be absorbed at all.
Isomer composition (lycopene-specific). Cis-lycopene is absorbed more efficiently than all-trans lycopene. Cooked tomato products (paste, sauce) shift the equilibrium towards cis; tomato oleoresin extracts also tend to be cis-enriched. This is the chemistry behind the "tomato paste with olive oil" pattern.
Sub-class targeting. Match the compound to the goal:
- Eye health (macula, AMD risk, screen fatigue) → lutein 10 mg + zeaxanthin 2 mg (the AREDS2 combination), optionally with meso-zeaxanthin.
- Skin (moisture, elasticity, modest photoprotection) → astaxanthin 3–6 mg + lycopene 8–16 mg + β-carotene 15 mg (avoiding β-carotene if the user smokes).
- Cardiovascular surrogate markers (BP, LDL oxidation) → lycopene 10–30 mg ± astaxanthin 6–12 mg.
- Weight, body fat, metabolic-syndrome adjunct → fucoxanthin 2.4–12 mg, typically in a combination formulation.
- Male prostate-health interest → lycopene 15–30 mg (with full FDA "very limited credible evidence" qualifier).
- Vitamin A status / pregnancy → β-carotene 3–6 mg (self-limiting, safer than preformed retinyl palmitate at high doses).
- General antioxidant / wellness → diverse whole-food intake is the highest-evidence approach.

When not to supplement a single carotenoid

Current or former smokers, or asbestos-exposed workers — avoid isolated β-carotene supplements ≥20 mg/day (CARET, ATBC).
Pregnant women — avoid high-dose β-carotene supplements (>6 mg/day) and avoid retinyl palmitate at supplement-level doses; prioritize food intake.
Infants and young children — single-compound carotenoid supplements are not generally recommended outside of WHO/UNICEF vitamin A deficiency programs.
Already well-nourished healthy adults — the cluster of cautionary trials (CARET, ATBC, SELECT) supports food-first patterns over isolated high-dose antioxidant supplements.

§10 Cross-Links to the Single-Compound Deep-Dive Pages

Sub-class	Deep-dive sub-page
Astaxanthin	/ingredients/astaxanthin/
Fucoxanthin	/ingredients/fucoxanthin/
Lutein	/ingredients/lutein/
Zeaxanthin	/ingredients/zeaxanthin/
Lycopene	/ingredients/lycopene/
β-Carotene	/ingredients/beta-carotene/

Related antioxidant network pages

Topic	Why it relates to carotenoids	Cross-link
Vitamin A (preformed retinol)	β-carotene is the food-based precursor; preformed vitamin A is not self-limiting and is teratogenic at high doses	/ingredients/vitamin-a/
Vitamin E (8-chemical family)	Fat-soluble chain-breaking antioxidant; CARET and SELECT share the cautionary lesson with the carotenoid family	/ingredients/vitamin-e/
Vitamin C	Water-soluble; regenerates oxidized vitamin E and certain carotenoids; part of the AREDS / AREDS2 formulations	/ingredients/vitamin-c/
CoQ10	Mitochondrial-membrane antioxidant complementing the carotenoid network	/ingredients/coq10/
Polyphenols (resveratrol, quercetin, EGCG)	Water-soluble plant antioxidants complementary to the lipid-soluble carotenoids	/ingredients/resveratrol/
Selenium	GPx cofactor; SELECT tested vitamin E and selenium together (negative for prostate cancer prevention)	/ingredients/selenium/

Carotenoids function as part of a broader antioxidant network. Vitamin C is water-soluble and recycles oxidized vitamin E and some carotenoids; vitamin E protects lipid membranes by chain breaking; CoQ10 operates in mitochondrial membranes; carotenoids occupy specific tissue compartments (β-carotene → vitamin A; lutein + zeaxanthin → macula; astaxanthin → broad multi-organ membranes; fucoxanthin → adipose UCP1 thermogenesis). Isolated high-dose supplementation of any single antioxidant has not consistently reproduced the broad disease-prevention pattern suggested by dietary intake, and several large trials (CARET, ATBC, SELECT) have found increased risk in specific subgroups. For most healthy adults, dietary patterns rich in colourful fruits, vegetables, marine algae, eggs, and whole foods remain the best evidence-based foundation for carotenoid intake.

§11 Frequently Asked Questions

The 12 most-asked questions about the carotenoid family across general web search and AI assistants. Answers reflect the evidence cited throughout this page and are intentionally concise; deeper detail lives in the relevant sections above and in the linked sub-pages.

1. What are carotenoids in one sentence?

Carotenoids are a family of 700+ fat-soluble plant and algal pigments — the same compounds that give carrots, tomatoes, marigolds, salmon flesh, and brown seaweed their characteristic colours — of which about 8 are nutritionally and clinically important in human health.

2. Is "carotenoid" a single substance?

No. It is a family label. The 8 most studied compounds are α-carotene, β-carotene, β-cryptoxanthin, lycopene (the carotenes) and lutein, zeaxanthin, astaxanthin, and fucoxanthin (the xanthophylls). Each has distinct chemistry and distinct human evidence.

3. Which carotenoids provide vitamin A?

Only three: α-carotene, β-carotene, and β-cryptoxanthin. They contain the β-ionone ring required by the BCO1 enzyme. Lycopene, lutein, zeaxanthin, astaxanthin, and fucoxanthin do not convert to vitamin A.

4. Is taking β-carotene safe?

Whole-food β-carotene from fruits and vegetables is safe and recommended. Isolated high-dose β-carotene supplementation (≥20 mg/day) is not safe for people who currently smoke, recently smoked, or have a history of asbestos exposure — two large randomized trials (CARET, ATBC) found it increased lung cancer in those populations. Non-smokers without these exposures generally tolerate β-carotene supplements well; sustained very high intake produces benign, reversible carotenodermia.

5. Should I take lutein and zeaxanthin together?

The clinical evidence base (AREDS2 and follow-on studies) is built on lutein 10 mg + zeaxanthin 2 mg per day in combination. Separate or reduced doses do not directly inherit the AREDS2 evidence.

6. Does lycopene prevent prostate cancer?

No claim of disease prevention can be made. In 2005, the US FDA reviewed the evidence and permitted only Qualified Health Claims with the wording: "Very limited credible evidence suggests that consuming lycopene may reduce the risk of prostate cancer; however, the FDA concludes that this evidence is very limited." The EFSA reviewed the same area and declined all functional health claims. Lycopene from tomato products has clearer evidence for improvements in cardiovascular surrogate markers (blood pressure, LDL oxidation) than for prostate-specific outcomes.

7. How does astaxanthin differ from other antioxidants?

Astaxanthin uniquely spans the entire lipid bilayer of cell membranes because its molecule carries polar hydroxyl and keto groups at both ends. This bipolar geometry, combined with its non-pro-oxidant chemistry, underlies its meta-analysis-supported effects on oxidative stress, inflammation markers, and skin moisture and elasticity. It does not provide vitamin A.

8. Is fucoxanthin a "fat-burning" carotenoid?

Fucoxanthin is the only carotenoid with a randomized-trial mechanism (UCP1 upregulation) that translates to measurable weight and body-fat changes in humans. The best-known weight-loss data come from a combination formulation (Xanthigen, with pomegranate seed oil), and most other supportive studies are small. Fucoxanthin is a credible metabolic-syndrome adjunct, not a stand-alone weight-loss treatment.

9. Can I get all the carotenoids I need from food?

For most people, yes. A varied diet that includes leafy greens (lutein, zeaxanthin), orange and red vegetables (β-carotene, α-carotene, lycopene), cooked tomato products with olive oil (lycopene), egg yolk (lutein, zeaxanthin), and salmon or seafood (astaxanthin) supplies the full pattern. Supplementation is most justified for specific tissue-targeted goals with strong evidence, such as lutein + zeaxanthin for established AMD risk.

10. Are carotenoids antioxidants or just colourants?

Both, and the two roles are linked. The conjugated double-bond chain that absorbs visible light (giving the colour) is also what quenches singlet oxygen and lipid peroxyl radicals (giving the antioxidant activity). However, "antioxidant" is a much narrower description than the actual range of effects, which include vitamin A precursor activity, macular pigment formation, transmembrane membrane stabilization, and UCP1 metabolic signaling.

11. Are carotenoid supplements regulated the same way worldwide?

No. Acceptable doses, permitted source materials, and allowable health claims vary substantially across China, the US, Brazil, and the EU. The EU is the strictest market for functional claims; the US uses Qualified Health Claims with required disclaimer wording for several carotenoid-cancer combinations; China and Brazil permit broader registered supplement claims within defined dose ceilings.

12. What about safety in pregnancy and childhood?

Food-level intake of all carotenoids is safe across pregnancy and childhood. Supplemental β-carotene up to ~6 mg/day is the conventional preference in pregnancy because it self-limits conversion to vitamin A, unlike preformed retinyl palmitate (teratogenic at high doses). Higher-dose carotenoid supplements in pregnancy and routine carotenoid supplementation in young children are not adequately studied and are not generally recommended.

Read the Evidence (deep dive long-form)

For deep-dive narrative on carotenoid antioxidant evidence (natural-source vs synthetic stereochemistry · bioavailability · antioxidant capacity · regulatory chronology and head-to-head clinical evidence) anchored on the astaxanthin family, see the dedicated evidence article:

Natural vs Synthetic Astaxanthin — Evidence Comparison — Haematococcus pluvialis natural carotenoid vs synthetic chemical synthesis · 28 PubMed-verified citations · Capelli 2013 antioxidant dataset · Zhou 2021 skin meta-analysis · Hecht 2025 paediatric digital eye strain RCT · peer cross-link to NAD⁺ 25-year evidence (mitochondrial / oxidative stress) + Omega-3 evidence history (shared cardiovascular endpoints).

The astaxanthin natural-vs-synthetic evidence article anchors the carotenoid cluster's natural-source quality argument. Cross-reading the long-form evidence article alongside this cluster hub builds the holistic carotenoid evidence picture from CARET / ATBC / AREDS2 / SELECT cluster-wide negative-honest framing → modern carotenoid quality differentiation.

References

All PMIDs verified by upstream source evidence pack (2026-05-24). Effect sizes are reported as published.

PMID 8602180 · Omenn GS, Goodman GE, Thornquist MD, et al. 1996. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease (CARET). New England Journal of Medicine 334(18):1150–1155.
PMID 8127329 · The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. 1994. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers (ATBC). New England Journal of Medicine 330(15):1029–1035.
PMID 24338499 · Virtamo J, Taylor PR, Kontto J, et al. 2014. Effects of α-tocopherol and β-carotene supplementation on cancer incidence and mortality: 18-year postintervention follow-up of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. International Journal of Cancer 135(1):178–185.
PMID 11594942 · Age-Related Eye Disease Study Research Group. 2001. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for AMD: AREDS Report No. 8. Archives of Ophthalmology 119(10):1417–1436.
PMID 23644932 · AREDS2 Research Group. 2013. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA 309(19):2005–2015.
PMID 24310343 · Chew EY, Clemons TE, SanGiovanni JP, et al. 2014. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 Report 3. JAMA Ophthalmology 132(2):142–149.
PMID 35653117 · Chew EY, Clemons TE, Agrón E, et al. 2022. Long-term outcomes of lutein, zeaxanthin and omega-3 fatty acids in AMD: AREDS2 10-year follow-up. JAMA Ophthalmology 140(7):692–698.
PMID 18086246 · Köpcke W, Krutmann J. 2008. Protection from sunburn with beta-Carotene — a meta-analysis (7 RCTs). Photochemistry and Photobiology 84(2):284–288.
PMID 17998490 · Grodstein F, Kang JH, Glynn RJ, Cook NR, Gaziano JM. 2007. A randomized trial of beta carotene supplementation and cognitive function in men: the Physicians' Health Study II. Archives of Internal Medicine 167(20):2184–2190.
PMID 28282701 · Imdad A, Mayo-Wilson E, Herzer K, Bhutta ZA. 2017. Vitamin A supplementation for preventing morbidity and mortality in children from six months to five years of age. Cochrane Database of Systematic Reviews CD008524.
PMID 28661438 · Stringham JM, Stringham NT, O'Brien KJ. 2017. Macular carotenoid supplementation improves visual performance, sleep quality, and adverse physical symptoms in those with high screen-time exposure. Foods 6(7):47.
PMID 28824416 · Hammond BR Jr, Miller LS, Bello MO, Lindbergh CA, Mewborn C, Renzi-Hammond LM. 2017. Effects of lutein/zeaxanthin supplementation on the cognitive function of community-dwelling older adults (CARES). Frontiers in Aging Neuroscience 9:254.
PMID 25976647 · Akuffo KO, Beatty S, Stack J, et al. 2015. Sustained supplementation and monitored response with differing carotenoid formulations in early AMD (MOST AMD). Eye (London) 29(7):902–912.
PMID 24621122 · Akuffo KO, Nolan J, Stack J, et al. 2014. The CREST (Central Retinal Enrichment Supplementation Trial): design and methodology. Ophthalmic Epidemiology 21(2):111–123.
PMID 27367585 · Nolan JM, Power R, Stringham J, et al. 2016. CREST Report 1: enrichment of macular pigment enhances contrast sensitivity in subjects free of retinal disease. Investigative Ophthalmology & Visual Science 57(7):3429–3439.
PMID 35091276 · Ma B, Lu J, Kang T, Zhu M, Xiong K, Wang J. 2022. Astaxanthin supplementation mildly reduced oxidative stress and inflammation biomarkers: a systematic review and meta-analysis of randomized controlled trials. Antioxidants 11(2):277.
PMID 34578794 · Donoso A, González-Durán J, Muñoz AA, González PA, Agurto-Muñoz C. 2021. Therapeutic uses of natural astaxanthin: an evidence-based review focused on human clinical trials. Pharmacological Research 166:105479.
PMID 38916710 · Fereidouni S, Kumar RB, et al. 2024. Astaxanthin co-supplementation and IVF/ICSI outcomes in women undergoing ART.
PMID 39269488 · Rodrigues KCS et al. 2025. Astaxanthin in assisted reproduction outcomes: a meta-analysis.
PMID 40014233 · Hecht F et al. 2025. Astaxanthin and visual fatigue / asthenopia in adults with high screen exposure.
PMID 35096941 · Tian L et al. 2021. Astaxanthin and asthenopia outcomes.
PMID 38243785 · Liu Y et al. 2024. Astaxanthin and exercise performance / recovery: a meta-analysis of 11 RCTs.
PMID 32755613 · Xia W et al. 2020. Astaxanthin cardiovascular biomarkers and lipid profile.
PMID 36999233 · Ciaraldi TP et al. 2023. Astaxanthin in prediabetes RCT.
PMID 34959932 · Urakaze M et al. 2021. Astaxanthin glycemic and insulin-sensitivity outcomes.
PMID 29384321 · Mashhadi NS et al. 2018. Astaxanthin glycemic outcomes RCT.
PMID 11340098 · Stahl W, Heinrich U, Wiseman S, Eichler O, Sies H, Tronnier H. 2001. Dietary tomato paste protects against UV-induced erythema in humans. Journal of Nutrition 131(5):1449–1451.
PMID 20854436 · Rizwan M, Rodriguez-Blanco I, Harbottle A, Birch-Machin MA, Watson RE, Rhodes LE. 2011. Tomato paste rich in lycopene protects against cutaneous photodamage in humans in vivo. British Journal of Dermatology 164(1):154–162.
PMID 27662341 · Grether-Beck S et al. 2017. Dermatology RCT on lycopene-rich tomato product for skin photoprotection.
PMID 28129549 · Cheng HM, Koutsidis G, Lodge JK, Ashor A, Siervo M, Lara J. 2017. Tomato and lycopene supplementation and cardiovascular risk factors: a systematic review and meta-analysis. Atherosclerosis / Critical Reviews in Food Science and Nutrition.
PMID 21163596 · Ried K, Fakler P. 2011. Protective effect of lycopene on serum cholesterol and blood pressure: meta-analyses of intervention trials. Maturitas 68(4):299–310.
PMID 26287411 · Chen J, Song Y, Zhang L. 2015. Lycopene/tomato consumption and prostate cancer risk: a meta-analysis. Medicine.
PMID 26372549 · Wang Y, Cui R, Xiao Y, Fang J, Xu Q. 2015. Effect of carotene and lycopene on the risk of prostate cancer. PLOS ONE.
PMID 19840063 · Abidov M, Ramazanov Z, Seifulla R, Grachev S. 2010. The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes, Obesity and Metabolism 12(1):72–81.
PMID 37405785 · López-Ramos A et al. 2023. Fucoxanthin 12 mg/day RCT in metabolic syndrome (n=28). Journal of Medicinal Food.
PMID 28620480 · Mikami N, Hosokawa M, Miyashita K, Sohma H, Ito YM, Kokai Y. 2017. Reduction of HbA1c levels by fucoxanthin-enriched akamoku oil related to the UCP1 polymorphism. Journal of Nutritional Science 6:e5.
PMID 33809062 · Shih PH et al. 2021. Low-molecular-weight fucoidan + high-stability fucoxanthin RCT in NAFLD. Marine Drugs.
PMID 39275314 · Yoo HJ et al. 2024. Phaeodactylum-derived fucoxanthin and cognitive outcomes. Nutrients.

Regulatory and Reference Sources

NIH Office of Dietary Supplements · Vitamin A and Carotenoids Fact Sheets for Health Professionals
U.S. FDA 2005 Qualified Health Claim Decision Letter (Docket 2004Q-0201) — Lycopene and prostate, ovarian, pancreatic, gastric cancer ("very limited credible evidence" wording)
EFSA ANS Panel 2012 — Scientific Opinion on lutein and zeaxanthin Art.13.1 health claim assessment (declined for macular health / visual maintenance)
EFSA 2010–2011 — Lycopene Art.13.1 health claim assessments (declined for cardiovascular, antioxidant, prostate, skin)
EFSA 2014/2020 — Astaxanthin from Haematococcus pluvialis Acceptable Daily Intake reassessment (0.2 mg/kg body weight/day)
NMPA 2010 Notice 17 — Haematococcus pluvialis Novel Food approval (China); synthetic astaxanthin prohibited in human food use
ANVISA RDC 243/2018 + IN 28/2018 + IN 418 — Brazil carotenoid positive list, dose ceilings, and astaxanthin "supports skin health" functional claim framework
IOM 2000 Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids (National Academies Press) — sets ADI references for the family

Cross-link to Related ASXAN Pages

Astaxanthin (deep-dive sub-page, published): bipolar transmembrane xanthophyll; oxidative-stress / inflammation / skin / ART meta-analytic evidence; Haematococcus pluvialis source biology; 4-region regulatory landscape including NMPA synthetic-astaxanthin ban.
Fucoxanthin (deep-dive sub-page, published): allenic xanthophyll; UCP1 upregulation thermogenic biology; Xanthigen weight RCT; Phaeodactylum diatom and brown-seaweed sources; Novel Food regulatory pathway.
Lutein (deep-dive sub-page): ε-ring dihydroxy xanthophyll; macular pigment biology; AREDS2 evidence base; EFSA Art.13.1 decline.
Zeaxanthin (deep-dive sub-page): β-ring dihydroxy xanthophyll and meso-zeaxanthin retinal generation; CREST / MOST AMD trial distinction with PMID severance.
Lycopene (deep-dive sub-page): acyclic carotene; cardiovascular surrogate markers; tomato-paste cis-isomerization absorption story; FDA Qualified Health Claims and EFSA Art.13.1 decline contrast.
β-Carotene (deep-dive sub-page): provitamin A pathway; CARET / ATBC smoker cautionary cluster; Cochrane vitamin A supplementation in children.
Vitamin E (cluster hub, D5 #16): the parallel 8-chemical fat-soluble antioxidant family — shares the cautionary-trial pattern (CARET combined β-carotene + retinol → vitamin E + SELECT increased prostate cancer in healthy men).
Coenzyme Q10: mitochondrial-membrane antioxidant complementing the lipid-phase carotenoid network.
Resveratrol: water-soluble polyphenol complementing the lipid-soluble carotenoids in the broader antioxidant network.

Educational Disclaimer

Educational reference page. Not medical advice. Carotenoid supplementation decisions — particularly isolated high-dose single-compound regimens, supplementation in current or former smokers (β-carotene), supplementation in pregnancy, and use of lutein + zeaxanthin in already-diagnosed age-related macular degeneration — should be made in consultation with a qualified healthcare provider. The disease-prevention and disease-treatment language of this page is constrained by the regulatory positions of the FDA (DSHEA structure/function disclaimer, Qualified Health Claims with mandatory disclaimer wording), EFSA (Art.13.1 declined for most carotenoid functional claims), NMPA (Novel Food and registered-supplement framework), and ANVISA (RDC 243/2018 positive list).

← All Ingredients